Correlation of CXCL10, tumor necrosis factor receptor type II, and galectin 9 with disease activity in juvenile dermatomyositis

Arthritis and Rheumatology

Volumn 66, Issue 8, 2014, Pages 2281-2289

  Bellutti Enders, F ^a,b   Van Wijk, F ^a   Scholman, R ^a   Hofer, M ^b   Prakken, B J ^a   Van Royen Kerkhof, A ^a   De Jager, W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATINE KINASE; CYCLOPHOSPHAMIDE; ECALECTIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; LACTATE DEHYDROGENASE; MEPREDNISONE; METHOTREXATE; PREDNISONE; RITUXIMAB; TACROLIMUS; TUMOR NECROSIS FACTOR RECEPTOR 2;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CHILDHOOD MYOSITIS ASSESSMENT SCALE; CLINICAL ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE DURATION; DUCHENNE MUSCULAR DYSTROPHY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; JUVENILE DERMATOMYOSITIS; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; PATIENT MONITORING; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RATING SCALE; SENSITIVITY AND SPECIFICITY; STEROID THERAPY; VISUAL ANALOG SCALE;

ADOLESCENT; BIOLOGICAL MARKERS; CHEMOKINE CXCL10; CHILD; CHILD, PRESCHOOL; DERMATOMYOSITIS; FEMALE; GALECTINS; HUMANS; MALE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II;

EID: 84905001177     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38676     Document Type: Article

References (49)

1. Wargula JC,. Update on juvenile dermatomyositis: new advances in understanding its etiopathogenesis. Curr Opin Rheumatol 2003; 15: 595-601.
2. Lundberg IE, Dastmalchi M,. Possible pathogenic mechanisms in inflammatory myopathies. Rheum Dis Clin North Am 2002; 28: 799-822.
3. Dawkins RL, Mastaglia FL,. Cell-mediated cytotoxicity to muscle in polymyositis: effect of immunosuppression. N Engl J Med 1973; 288: 434-8.
4. Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009; 60: 3436-46.
5. Feldman BM, Rider LG, Reed AM, Pachman LM,. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008; 371: 2201-12.
6. Symmons DP, Sills JA, Davis SM,. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 1995; 34: 732-6.
7. Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, et al, the Childhood Myositis Heterogeneity Collaborative Study Group. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 2013; 92: 25-41.
8. Stringer E, Singh-Grewal D, Feldman BM,. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum 2008; 58: 3585-92.
9. Hasija R, Pistorio A, Ravelli A, Demirkaya E, Khubchandani R, Guseinova D, et al, for the Pediatric Rheumatology International Trials Organization. Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study. Arthritis Rheum 2011; 63: 3142-52.
10. Pachman LM,. Juvenile dermatomyositis: pathophysiology and disease expression. Pediatr Clin North Am 1995; 42: 1071-98.
11. Ramanan AV, Campbell-Webster N, Ota S, Parker S, Tran D, Tyrrell PN, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 2005; 52: 3570-8.
12. Christen-Zaech S, Seshadri R, Sundberg J, Paller AS, Pachman LM,. Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis Rheum 2008; 58: 571-6.
13. Bader-Meunier B, Decaluwe H, Barnerias C, Gherardi R, Quartier P, Faye A, et al, for the Club Rhumatismes et Inflammation. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol 2011; 38: 1436-40.
14. Holzer U, van Royen-Kerkhof A, van der Torre P, Kuemmerle-Deschner J, Well C, Handgretinger R, et al. Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis. Scand J Rheumatol 2010; 39: 88-92.
15. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al, and the RIM Study Group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013; 65: 314-24.
16. Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA,. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 2008; 47: 877-80.
17. Pereira RM, Freire de Carvalho J,. Glucocorticoid-induced myopathy. Joint Bone Spine 2011; 78: 41-4.
18. Nistala K, Varsani H, Wittowski H, Vogl T, Krol P, Shah V, et al. Myeloid related protein induces muscle derived inflammatory mediators in juvenile dermatomyositis. Arthritis Res Ther 2013; 15: R131.
19. Reed AM, Peterson E, Bilgic H, Ytterberg SR, Amin S, Hein MS, et al. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. Arthritis Rheum 2012; 64: 4078-86.
20. De Jager W, Hoppenreijs EP, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ,. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis 2007; 66: 589-98.
21. Bohan A, Peter JB,. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
22. Lovell DJ, Lindsley CB, Rennebohm RM, Ballinger SH, Bowyer SL, Giannini EH, et al, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum 1999; 42: 2213-9.
23. Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C, et al, for the Paediatric Rheumatology International Trials Organisation (PRINTO). The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis 2013; 72: 686-93.
24. Quinones R, Morgan GA, Amoruso M, Field R, Huang CC, Pachman LM,. Lack of achievement of a full score on the Childhood Myositis Assessment Scale by healthy four-year-olds and those recovering from juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2013; 65: 1697-701.
25. De Jager W, Prakken BJ, Bijlsma JW, Kuis W, Rijkers GT,. Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J Immunol Methods 2005; 300: 124-35.
26. Xiong N, Fu Y, Hu S, Xia M, Yang J,. CCR10 and its ligands in regulation of epithelial immunity and diseases. Protein Cell 2012; 3: 571-80.
27. De Paepe B, Creus KK, De Bleecker JL,. Role of cytokines and chemokines in idiopathic inflammatory myopathies. Curr Opin Rheumatol 2009; 21: 610-6.
28. Hehlgans T, Pfeffer K,. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005; 115: 1-20.
29. + regulatory T cells inhibits the induction of inflammatory mediators. J Immunol 2008; 180: 2747-51.
30. Liu FT, Yang RY, Hsu DK,. Galectins in acute and chronic inflammation. Ann N Y Acad Sci 2012; 1253: 80-91.
31. Deshmane SL, Kremlev S, Amini S, Sawaya BE,. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009; 29: 313-26.
32. Gregoire C, Chasson L, Luci C, Tomasello E, Geissmann F, Vivier E, et al. The trafficking of natural killer cells. Immunol Rev 2007; 220: 169-82.
33. Luther SA, Cyster JG,. Chemokines as regulators of T cell differentiation. Nat Immunol 2001; 2: 102-7.
34. Lopez de Padilla CM, Vallejo AN, Lacomis D, McNallan K, Reed AM,. Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum 2009; 60: 1160-72.
35. Robertson MJ,. Role of chemokines in the biology of natural killer cells. J Leukoc Biol 2002; 71: 173-83.
36. + T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 2011; 34: 108-21.
37. Crescioli C, Sottili M, Bonini P, Cosmi L, Chiarugi P, Romagnani P, et al. Inflammatory response in human skeletal muscle cells: CXCL10 as a potential therapeutic target. Eur J Cell Biol 2012; 91: 139-49.
38. Yellin M, Paliienko I, Balanescu A, Ter-Vartanian S, Tseluyko V, Xu LA, et al. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2012; 64: 1730-9.
39. De Bleecker JL, Meire VI, Declercq W, Van Aken EH,. Immunolocalization of tumor necrosis factor-α and its receptors in inflammatory myopathies. Neuromuscul Disord 1999; 9: 239-46.
40. Pachman LM, Fedczyna TO, Lechman TS, Lutz J,. Juvenile dermatomyositis: the association of the TNFα-308A allele and disease chronicity. Curr Rheumatol Rep 2001; 3: 379-86.
41. Rouster-Stevens KA, Ferguson L, Morgan G, Huang CC, Pachman LM,. Pilot study of etanercept in patients with refractory juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2014; 66: 783-7.
42. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 6: 1245-52.
43. Golden-Mason L, McMahan RH, Strong M, Reisdorph R, Mahaffey S, Palmer BE, et al. Galectin-9 functionally impairs natural killer cells in humans and mice. J Virol 2013; 87: 4835-45.
44. Seki M, Sakata KM, Oomizu S, Arikawa T, Sakata A, Ueno M, et al. Beneficial effect of galectin 9 on rheumatoid arthritis by induction of apoptosis of synovial fibroblasts. Arthritis Rheum 2007; 56: 3968-76.
45. Bi S, Hong PW, Lee B, Baum LG,. Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry. Proc Natl Acad Sci U S A 2011; 108: 10650-5.
46. Gooden MJ, Wiersma VR, Samplonius DF, Gerssen J, van Ginkel RJ, Nijman HW, et al. Galectin-9 activates and expands human T-helper 1 cells. PLoS One 2013; 8: e65616.
47. Ishikawa A, Imaizumi T, Yoshida H, Nishi N, Nakamura T, Hirashima M, et al. Double-stranded RNA enhances the expression of galectin-9 in vascular endothelial cells. Immunol Cell Biol 2004; 82: 410-4.
48. Imaizumi T, Kumagai M, Sasaki N, Kurotaki H, Mori F, Seki M, et al. Interferon-γ stimulates the expression of galectin-9 in cultured human endothelial cells. J Leukoc Biol 2002; 72: 486-91.
49. Li X, Zhao YQ, Li CW, Yuan FL,. T cell immunoglobulin-3 as a new therapeutic target for rheumatoid arthritis. Expert Opin Ther Targets 2012; 16: 1145-9.